Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs Sevoflurane for Recovery Quality in TURBT
NCT05356091Completed
- Sponsor
- Kangbuk Samsung Hospital
- Start
- Dec 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of remimazolam in bladder cancer (2 arms), sponsored by Kangbuk Samsung Hospital. Primary endpoint: Quality of Recovery-15. Started Dec 2022; status: completed.
02
Drugs
remimazolam
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT05356091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05356091.